Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Immunomedics (IMMU) Share Price
Media headlines about Immunomedics (NASDAQ:IMMU) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immunomedics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.8412738891851 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several equities research analysts have commented on IMMU shares. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Immunomedics in a report on Friday, July 14th. BidaskClub downgraded shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Immunomedics in a report on Monday, July 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Immunomedics currently has a consensus rating of “Buy” and a consensus target price of $15.33.
Immunomedics (NASDAQ IMMU) traded up $1.96 during midday trading on Friday, reaching $12.40. 8,081,900 shares of the company’s stock traded hands, compared to its average volume of 3,046,555. Immunomedics has a 1-year low of $2.38 and a 1-year high of $14.48. The company has a current ratio of 1.29, a quick ratio of 1.28 and a debt-to-equity ratio of -1.65.
Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings results on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.13). The firm had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $0.75 million. During the same quarter in the previous year, the company posted ($0.17) EPS. The firm’s revenue for the quarter was down 31.2% on a year-over-year basis. analysts anticipate that Immunomedics will post -0.41 earnings per share for the current fiscal year.
In other news, Director Cynthia L. Goldenberg sold 40,000 shares of the company’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $10.72, for a total transaction of $428,800.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David M. Goldenberg sold 20,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $12.64, for a total value of $252,800.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 100,000 shares of company stock worth $1,051,200. Company insiders own 6.60% of the company’s stock.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.